ľ�ϸ���Ӱ��

We focus on tackling complex challenges in joint replacement—particularly when implants fail due to infection. Our mission is to better understand implant-related infections and to develop new strategies to restore bone and secure implants.

While joint replacement is generally a highly successful procedure, our academic practice often deals with difficult cases where implants fail, for example due to severe bone loss or implant-associated infection. Implant infection is a devastating complication, frequently accompanied by large bone defects. Treatment usually requires removal of the infected material and placement of a revision implant. Because such implants are often not available off the shelf, we integrate advanced 3D printing techniques to improve surgical outcomes.

In collaboration with medical microbiology, we conduct both in vitro and in vivo studies to investigate bacterial biofilm growth on implants. We are also developing minimally invasive and non-surgical treatment approaches. One strategy involves novel implant coatings that release bactericidal compounds locally to prevent infection (collaboration with Research Group on “Designer Biomaterials”). Another approach uses antibodies or aptamers that specifically target biofilm-forming bacteria. We are currently exploring ways to attach radioactive elements to these infection-seeking antibodies to eradicate established infections, or use antibodies or aptamers to directly interfere with bacteria and improve eradication efficacy of the immune system.

Our group brings together clinical innovation and fundamental science to advance the treatment of infected and failed joint implants. By combining surgical technologies such as 3D printing with microbiological research and novel therapeutic strategies, we aim to create better options for both prevention and treatment of severe complications in joint reconstruction.

People